Walgreens earnings slide as number of vaccinations wane
Associated PressA big opioid settlement and a COVID-19 vaccine slowdown dragged on third-quarter earnings for Walgreens, but the drugstore chain still topped expectations. Walgreens CEO Rosalind Brewer told analysts in January that the company would explore strategic options for that business so it could focus more on U.S. health care. Brewer said then that Walgreens was creating an entity “that does much more than just dispense pharmaceuticals.” The company announced the creation of a Walgreens Health business segment last fall. Selling the Boots business would have given Walgreens more financial flexibility and allowed its leaders to focus on these newer initiatives, Edward Jones analyst John Boylan said in an email. He added that keeping the Boots business “could modestly complicate the process.” Company shares slid nearly 4% to $39.27 after markets opened Thursday and broader indexes also sank.